Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
J-Pharma chases Telix in LAT1
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
There’s no stopping CDH17
No fewer than four ADCs with this target start human testing.
Baili moves its CD33 conjugate into advanced trials
The company is set to start a phase 2/3 trial this month.
Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
Adlai puts its faith in pan-RAS
The company’s AN9025 will shortly enter phase 1.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
